TLSI Overview

TriSalus Life Sciences, Inc. is an oncology-focused medical technology company. The Company is seeking to transform outcomes for patients with solid tumors by integrating its delivery technology with standard-of-care therapies, and with its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical-stage investigational immunotherapy. The Company’s two Food and Drug Administration (FDA)-cleared devices use its proprietary Pressure-Enabled Drug Delivery (PEDD) approach to deliver a range of therapeutics: the TriNav Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD technology is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas.

Wall Street analysts forecast TLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLSI is11.92 USD with a low forecast of 10.00 USD and a high forecast of 16.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

TriSalus Life Sciences Inc revenue for the last quarter amounts to 13.21M USD, increased 59.85

TriSalus Life Sciences Inc. EPS for the last quarter amounts to -0.21 USD, decreased -47.50

TriSalus Life Sciences Inc (TLSI) has 102 emplpoyees as of April 03 2026.

Today TLSI has the market capitalization of 260.40M USD.